PFIZER INC (PFE) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-28..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-28..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-28..
Borrowing debt
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 2.60B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 60.49B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | Commercial Paper |
| Cash and current securities | 8.26B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 201.13B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | (m) | $2.60B | $60.49B | (m) | $8.26B | $201.13B | (m) |
| 2026-03-29 | (m) | (m) | $3.86B | $60.56B | (m) | $9.89B | $207.62B | (m) |
| 2025-12-31 | $64.64B | $54.31B | $3.00B | $61.64B | $0.00 | $10.32B | $208.16B | 31.05% |
| 2025-09-28 | $61.66B | $50.19B | $4.25B | $57.41B | $0.00 | $11.47B | $208.73B | 29.54% |
| 2025-06-29 | $61.75B | $50.59B | $4.25B | $57.50B | $0.00 | $11.16B | $206.09B | 29.96% |
| 2025-03-30 | $61.54B | $46.16B | $3.75B | $57.64B | $155.00M | $15.38B | $208.03B | 29.58% |
| 2024-12-31 | $63.60B | $51.68B | $3.75B | $57.41B | $2.45B | $11.92B | $213.40B | 29.81% |
| 2024-09-29 | $67.59B | $59.65B | $3.75B | $58.00B | $5.84B | $7.94B | $219.48B | 30.80% |
| 2024-06-30 | $69.22B | $63.76B | $3.75B | $57.51B | $7.96B | $5.45B | $216.19B | 32.02% |
| 2024-03-31 | $69.24B | $60.30B | $1.00B | $61.31B | $6.93B | $8.94B | $221.09B | 31.32% |
| 2023-12-31 | $71.76B | $64.50B | $2.25B | $61.54B | $7.96B | $7.25B | $226.50B | 31.68% |
| 2023-10-01 | (m) | (m) | $2.26B | $61.05B | (m) | $29.39B | $215.02B | (m) |
| 2023-07-02 | (m) | (m) | $3.56B | $61.36B | (m) | $26.72B | $220.17B | (m) |
| 2023-04-02 | (m) | (m) | $3.57B | $31.70B | (m) | $18.28B | $195.62B | (m) |
| 2022-12-31 | (m) | (m) | $2.56B | $32.88B | (m) | $19.16B | $197.21B | (m) |
| 2022-10-02 | (m) | (m) | $2.57B | $32.63B | (m) | $21.47B | $195.35B | (m) |
| 2022-07-03 | (m) | (m) | $1.28B | $34.29B | (m) | $27.40B | $195.29B | (m) |
| 2022-04-03 | (m) | (m) | $260.00M | $35.66B | (m) | $19.81B | $183.84B | (m) |
| 2021-12-31 | $37.83B | $13.87B | $1.64B | $36.20B | $0.00 | $23.96B | $181.48B | 20.85% |
| 2021-10-03 | $39.01B | $14.16B | $2.66B | $36.25B | $100.00M | $24.85B | $179.19B | 21.77% |
| 2021-07-04 | $39.14B | $22.74B | $3.69B | $35.35B | $100.00M | $16.40B | $169.92B | 23.03% |
| 2021-04-04 | $39.44B | $29.38B | $3.68B | $35.35B | $416.00M | $10.06B | $158.82B | 24.83% |
| 2020-12-31 | $39.69B | $28.20B | $2.00B | $37.13B | $556.00M | $11.49B | $154.23B | 25.74% |
| 2020-09-27 | $62.92B | $53.48B | $2.15B | $49.78B | $10.99B | $9.45B | $178.98B | 35.16% |
| 2020-06-28 | $62.67B | $53.20B | $1.48B | $50.53B | $10.66B | $9.47B | $177.93B | 35.22% |
| 2020-03-29 | $51.53B | $46.56B | $337.00M | $36.28B | $14.91B | $4.96B | $166.34B | 30.98% |
| 2019-12-31 | $51.33B | $43.34B | $1.46B | $35.95B | $13.91B | $7.99B | $167.49B | 30.65% |
| 2019-09-29 | $51.39B | $44.33B | $2.43B | $36.04B | $12.91B | $7.05B | $170.45B | 30.15% |
| 2019-06-30 | $45.01B | $38.20B | $2.14B | $36.17B | $6.71B | $6.81B | $156.20B | 28.82% |
| 2019-03-31 | $44.15B | $35.03B | $4.47B | $35.73B | $3.95B | $9.12B | $155.42B | 28.41% |
| 2018-12-31 | $40.78B | $24.55B | $4.78B | $32.91B | $3.10B | $16.23B | $159.42B | 25.58% |
| 2018-09-30 | $40.51B | $25.69B | $4.25B | $33.65B | $2.60B | $14.81B | $167.84B | 24.13% |
| 2018-07-01 | $40.00B | $29.07B | $4.26B | $28.93B | $6.80B | $10.92B | $164.98B | 24.24% |
| 2018-04-01 | $40.59B | $31.29B | $4.76B | $31.83B | $4.00B | $9.31B | $164.61B | 24.66% |
| 2017-12-31 | $43.18B | $24.35B | $3.55B | $33.54B | $6.10B | $18.84B | $171.80B | 25.14% |
| 2017-10-01 | (m) | (m) | $3.07B | $34.50B | (m) | (m) | $172.15B | (m) |
| 2017-07-02 | (m) | (m) | $3.07B | $34.19B | (m) | (m) | $168.56B | (m) |
| 2017-04-02 | (m) | (m) | $3.29B | $36.33B | (m) | (m) | $168.78B | (m) |
| 2016-12-31 | (m) | (m) | $4.22B | $31.40B | (m) | (m) | $171.62B | (m) |
| 2016-10-02 | (m) | (m) | (m) | $30.44B | (m) | (m) | $178.43B | (m) |
| 2016-07-03 | (m) | (m) | (m) | $30.46B | (m) | (m) | $170.66B | (m) |
| 2016-04-03 | (m) | (m) | (m) | $27.82B | (m) | (m) | $162.93B | (m) |
| 2015-12-31 | (m) | (m) | $3.72B | $28.82B | (m) | (m) | $167.46B | (m) |
| 2015-09-27 | (m) | (m) | (m) | $29.08B | (m) | (m) | $170.87B | (m) |
| 2015-06-28 | (m) | (m) | (m) | $26.73B | (m) | (m) | $160.88B | (m) |
| 2015-03-29 | (m) | (m) | (m) | $29.37B | (m) | (m) | $160.64B | (m) |
| 2014-12-31 | (m) | (m) | $3.01B | $31.54B | (m) | (m) | $169.27B | (m) |
| 2014-09-28 | (m) | (m) | (m) | $31.67B | $0.00 | (m) | $171.36B | (m) |
| 2014-06-29 | (m) | (m) | (m) | $32.27B | $0.00 | (m) | $172.61B | (m) |
| 2014-03-30 | (m) | (m) | (m) | $27.65B | $3.70B | (m) | $171.81B | (m) |
| 2013-12-31 | $35.52B | (m) | $2.06B | $30.46B | $3.00B | (m) | $172.10B | 20.64% |
| 2013-09-29 | (m) | (m) | (m) | $31.81B | (m) | (m) | $175.52B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $31.53B | (m) | (m) | $179.34B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $31.48B | (m) | (m) | $187.40B | (m) |
| 2012-12-31 | (m) | (m) | $2.45B | $31.04B | (m) | (m) | $185.80B | (m) |
| 2012-09-30 | (m) | (m) | (m) | $31.08B | (m) | (m) | $182.60B | (m) |
| 2012-07-01 | (m) | (m) | (m) | $30.87B | (m) | (m) | $182.84B | (m) |
| 2012-04-01 | (m) | (m) | (m) | $33.54B | (m) | (m) | $185.68B | (m) |
| 2011-12-31 | (m) | (m) | $6.00M | $34.93B | (m) | (m) | $188.00B | (m) |
| 2011-10-02 | (m) | (m) | (m) | $35.40B | (m) | (m) | $196.13B | (m) |
| 2011-07-03 | (m) | (m) | (m) | $35.72B | (m) | (m) | $195.90B | (m) |
| 2011-04-03 | (m) | (m) | (m) | $35.31B | (m) | (m) | $194.96B | (m) |
| 2010-12-31 | (m) | (m) | $3.50B | $38.41B | (m) | (m) | $195.01B | (m) |
| 2010-10-03 | (m) | (m) | (m) | $39.01B | (m) | (m) | $191.41B | (m) |
| 2010-07-04 | (m) | (m) | (m) | $37.77B | (m) | (m) | $191.07B | (m) |
| 2010-04-04 | (m) | (m) | (m) | $38.28B | (m) | (m) | $195.11B | (m) |
| 2009-12-31 | (m) | (m) | $27.00M | $43.19B | (m) | (m) | $212.95B | (m) |
| 2009-09-27 | (m) | (m) | (m) | $32.40B | (m) | (m) | $141.29B | (m) |
| 2009-06-28 | (m) | (m) | (m) | $31.86B | (m) | (m) | $139.34B | (m) |
| 2008-12-31 | (m) | (m) | (m) | $7.96B | (m) | (m) | $111.15B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |